An interventional study of prescribing anticoagulant therapy in Anticoagulants, sponsored by I.M. Sechenov First Moscow State Medical University. Completed. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-04-08.
Sponsored by I.M. Sechenov First Moscow State Medical University · Not applicable, Interventional, and Treatment
Single-institution uncontrolled open-label trial.
The single-institution uncontrolled open-label trial is to optimize the anticoagulant therapy in the out-patient practice.
The study embraces patients who are advised to take the anticoagulant therapy for some reasons. The study has two phases - a retrospective part and a concurrent part. At the first phase, researchers analyze the compliance with the anticoagulant therapy in the real clinical practice. At the concurrent phase, researchers conduct a single-institution uncontrolled open-label trial to evaluate the effectiveness, safety of the anticoagulant therapy and compliance with it at the antithrombotic therapy control ward, and estimate the glomerular filtration rate in patients taking the anticoagulant therapy.
I.M. Sechenov First Moscow State Medical University is the lead sponsor of 133 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Non-inclusion criteria:
pregnancy and lactation
The study embraces patients who are advised to take the anticoagulant therapy (as per the European Society of Cardiology Guidelines). The study evaluates the compliance with the anticoagulant therapy, safety and effectiveness, mortality
Other: prescribing anticoagulant therapy
Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
kidney compliance with the anticoagulant therapy and its safety and trends in the kidney function
During a visit to the clinic, the patient will be surveyed and tested for the creatinine level
Time frame: Evaluation of GFR, bleeding and thrombotic complications after 2 years
death due to any cause
phone survey when patients are invited to the clinic
Time frame: in six years after the anticoagulant therapy is prescribed
cardiovascular mortality
Phone survey when patients are invited to the clinic. The term cardiovascular mortality means a set of fatal heart attacks, fatal strokes, sudden death, fatal thromboembolism.
Time frame: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 2 years
kidney function trend
phone survey when patients are invited to the clinic for testing the creatinine level and further estimation of the glomerular filtration rate
Time frame: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 3 years
intensive bleeding
phone survey when patients are invited to the clinic.
Time frame: Evaluation of GFR, bleeding and thrombotic complications and cardiac mortality after 6 years
frequency of thromboembolic events
patients will be surveyed upon their visit to the clinic. Thromboembolic events shall mean non-fatal embolic strokes, systemic embolism, acute coronary syndrome (to be corroborated with documents).
Time frame: in 1-2-3-6 years after the anticoagulant therapy is prescribed
minor bleeding
Minor bleeding shall mean any visually observed bleeding, including that discovered with various imaging methods, which cause a decrease in HB by less than 30 GM/DL or Ht by less than 9%.
Time frame: in 1-2-3-6 years after the anticoagulant therapy is prescribed
No study locations are listed for this record.
Plan to share: No — ethics committee requirement
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I.M. Sechenov First Moscow State Medical University